RNA Therapeutics Market (2026-2036)
The global RNA therapeutics market was valued at USD 16.69 billion in 2025. This market is expected to reach USD 40.98 billion by 2036 from an estimated USD 18.44 billion in 2026, growing at a CAGR of 8.3% during the forecast period 2026–2036.
- Published
- Apr 2026
- Pages
- 271
- Format
- PDF + Excel
- Report ID
- MR-1874
- Base year
- 2025
- 2025 · BASELINE
- $16.69B
- 2036
- $40.98B
- CAGR 2026–2036
- 8.3%
2025 baseline · 2026–2036 forecast at 8.3% CAGR · hover a bar for the value
Key highlights
The global RNA therapeutics market is projected to reach USD 40.98 billion by 2036.
The market is expected to grow at a CAGR of 8.3% during the forecast period 2026–2036.
The global RNA therapeutics market was valued at USD 16.69 billion in 2025 and is estimated to reach USD 18.44 billion in 2026.
North America is expected to dominate the global RNA therapeutics market with the largest market share in 2026, driven by a robust biotechnology ecosystem, high R&D investment, and a favorable regulatory environment for orphan drugs and advanced therapies.
Asia Pacific is projected to witness the fastest growth during the forecast period, fueled by increasing healthcare expenditure, a growing burden of chronic diseases, and expanding biopharmaceutical manufacturing capabilities in China, India, and South Korea.
By technology type, the RNA interference (RNAi) segment is projected to register a high CAGR, driven by the increasing approval of siRNA drugs for rare and chronic metabolic disorders.
By indication, the infectious diseases segment is expected to account for the largest share in 2026, while the oncology segment is projected to register the highest CAGR as personalized RNA cancer vaccines enter the commercial phase.
By delivery platform, Lipid Nanoparticles (LNPs) are expected to account for the largest share in 2026, while Conjugate-Based Delivery (e.g., GalNAc) is projected to grow rapidly due to its high efficiency in liver-targeted therapies.
By end user, hospitals and clinics are expected to account for the largest share in 2026, while pharmaceutical and biotechnology companies are projected to register the highest CAGR during the forecast period.
Report summary
| Particulars | Details |
|---|---|
| Market Size by 2036 | USD 40.98 Billion |
| Market Size in 2026 | USD 18.44 Billion |
| Market Size in 2025 | USD 16.69 Billion |
| Revenue Growth Rate (2026–2036) | CAGR of 8.3% |
| Format | PDF, Excel & Cloud Portal · 271 pages |
| Dominating Technology Type | mRNA Therapeutics |
| Fastest Growing Technology Type | RNA Interference (RNAi) |
| Dominating Indication | Infectious Diseases |
| Fastest Growing Indication | Oncology |
| Dominating Delivery Platform | Lipid Nanoparticles (LNPs) |
| Fastest Growing Delivery Platform | Conjugate-Based Delivery (GalNAc) |
| Dominating End User | Hospitals and Clinics |
| Fastest Growing End User | Pharmaceutical & Biotech Companies |
| Dominating Geography | North America |
| Fastest Growing Geography | Asia Pacific |
| Base Year | 2025 |
| Forecast Period | 2026 to 2036 |
Report overview
Segments covered: technology type, indication, delivery platform, end user.
The global RNA therapeutics market encompasses a diverse range of technologies designed to target disease at the genetic level by utilizing ribonucleic acid (RNA) molecules. This includes messenger RNA (mRNA) for protein expression, RNA interference (RNAi) for gene silencing, antisense oligonucleotides (ASOs) for splicing modulation, and aptamers for protein binding. These therapies represent a paradigm shift in medicine, moving from traditional small molecules and biologics to programmable genetic medicines.
RNA therapeutics function as a versatile platform capable of addressing "undruggable" targets, enabling the treatment of rare genetic disorders, complex cancers, and infectious diseases. The market is characterized by rapid technological evolution, particularly in delivery systems like Lipid Nanoparticles (LNPs) and GalNAc conjugates, which have overcome historical challenges related to RNA stability and cellular uptake.
The growth of the global RNA therapeutics market is primarily driven by the increasing prevalence of chronic and genetic diseases, coupled with the validated success of mRNA technology during the pandemic. The ability to rapidly design and manufacture RNA-based candidates makes them ideal for personalized medicine and rapid response to emerging pathogens. Furthermore, significant venture capital and institutional investment in the biotechnology sector are accelerating the clinical pipeline.
However, the market faces constraints such as high development and manufacturing costs, particularly for personalized therapies. Delivery remains a challenge for extra-hepatic tissues, and the complex regulatory landscape for gene-based therapies can lead to extended approval timelines. Additionally, the requirement for ultra-cold chain logistics for certain mRNA products poses a barrier in developing regions.
Despite these challenges, opportunities abound in the expansion of RNA therapies into oncology and cardiovascular diseases. The development of next-generation delivery platforms, such as exosomes and circular RNA (circRNA), promises improved stability and tissue specificity. Strategic collaborations between big pharma and nimble biotech firms are also expected to drive market expansion through the forecast period.
Report infographic
Market dynamics
2 factors across 1 forceExpansion of mRNA-Based Therapeutics Beyond Vaccines into Oncology
The most significant trend in the RNA therapeutics market is the pivot of mRNA technology from prophylactic vaccines to therapeutic applications, particularly in oncology. Companies like Moderna and BioNTech are advancing personalized cancer vaccines that encode patient-specific neoantigens to trigger a targeted immune response. This shift is transforming the oncology landscape, offering a highly precise alternative to traditional chemotherapy and even existing immunotherapies. The integration of mRNA with checkpoint inhibitors is showing promising results in clinical trials for melanoma and non-small cell lung cancer, signaling a new era of "programmable" cancer treatment.
Advancements in Extra-Hepatic Delivery Technologies
While the liver has been the primary target for RNA therapies due to the natural accumulation of delivery vehicles like LNPs and GalNAc conjugates, a major trend is the development of technologies for extra-hepatic delivery. Researchers and companies are engineering novel ligands and viral-like particles to target the lungs, central nervous system (CNS), and heart. This expansion is critical for treating neurological disorders like Alzheimer’s and Huntington’s disease, as well as cystic fibrosis. The move toward tissue-specific delivery is expected to significantly expand the addressable market for RNA therapeutics over the next decade.
Rise of RNA Interference (RNAi) for Chronic Disease Management
RNA interference (RNAi) is transitioning from a tool for rare disease treatment to a mainstream platform for chronic disease management. The approval of siRNA drugs for conditions like primary hyperoxaluria and hereditary transthyretin-mediated amyloidosis has paved the way for targeting more common conditions. A key trend is the development of long-acting RNAi therapies for cardiovascular health, such as Inclisiran for LDL cholesterol reduction, which requires only twice-yearly dosing. This "vaccine-like" approach to chronic disease management is expected to drive high volume adoption and market growth.
Table of contents
12 chapters · 162 sections · 271 pages · click to expandSegmental analysis
| Segment | Largest share (2026) | Fastest growth (2026–2036) |
|---|---|---|
| By Technology Type | MRNA | RNA interference (RNAi) |
| By Indication | Infectious Diseases | Oncology |
| By Delivery Platform | Lipid Nanoparticles (LNPs) | Conjugate-Based Delivery (e.g., GalNAc) |
| By End User | Hospitals and Clinics | Pharmaceutical and biotechnology companies |
By Technology Type
- The mRNA Segment to Dominate the Global RNA Therapeutics Market
- The mRNA therapeutics segment is expected to account for the largest share of RNA therapeutics market.
- The large share of this segment is attributed to the high capital expenditure cycle in mRNA manufacturing and the broad clinical pipeline targeting both infectious diseases and oncology.
- The hardware and infrastructure for mRNA production are in active large-volume procurement across global biopharmaceutical hubs.
- However, the RNA interference (RNAi) segment is poised to grow at the highest CAGR of during the forecast period.
- The high growth of this segment is attributed to the growing adoption of GalNAc-conjugation for liver targeting, the increasing deployment of siRNA for chronic metabolic disorders, and the rising number of clinical milestones in the RNAi pipeline.
By Indication
- Infectious Diseases to Hold the Largest Share
- The infectious diseases segment is expected to account for the largest share of RNA therapeutics market.
- The large share of this segment is attributed to the continued demand for mRNA-based respiratory vaccines and the active development of next-generation candidates for HIV, Zika, and malaria.
- The oncology segment is poised to grow at the highest CAGR of during the forecast period.
- This growth is fueled by the transition of several personalized mRNA cancer vaccines and RNAi-based tumor suppressors into late-stage clinical trials.
- The ability of RNA therapies to target previously "undruggable" oncogenes and modulate the tumor microenvironment positions this segment for explosive growth.
By Delivery Platform
- Lipid Nanoparticles (LNPs) to Dominate the Global Market
- The Lipid Nanoparticles (LNPs) segment is expected to account for the largest share of RNA therapeutics market.
- The large share of this segment is attributed to the high volume of mRNA vaccines utilizing LNP technology and the established safety and efficacy profile of LNPs in global clinical applications.
- However, the Conjugate-Based Delivery (e.g., GalNAc) segment is poised to grow at the highest CAGR of during the forecast period.
- The high growth of this segment is attributed to the superior stability and tissue-specific targeting of GalNAc for liver-based therapies, which reduces off-target effects and enables subcutaneous administration, improving patient compliance.
By End User
- Hospitals and Clinics to Hold the Largest Share
- The hospitals and clinics segment is expected to account for the largest share of RNA therapeutics market.
- The large share of this segment is attributed to the high volume of vaccine administration and the increasing integration of RNA-based therapies into standard clinical practice for rare and chronic diseases.
- The pharmaceutical and biotechnology companies segment is poised to grow at the highest CAGR of during the forecast period.
- This growth is attributed to the rapid expansion of internal R&D programs, the increasing number of strategic collaborations for RNA platform development, and the rising investment in proprietary manufacturing facilities to secure supply chains.
Geographic analysis
North America
Fastest growthNorth America is expected to account for the largest share of RNA therapeutics market. The large share of this region is attributed to the presence of industry giants like Moderna and Alnylam, a high concentration of research universities, and a supportive ecosystem for orphan drug development. The U.S. FDA’s proactive stance on advanced therapy medicinal products (ATMPs) further bolsters this region. By Geography: North America to Dominate; Asia Pacific to Grow Fastest
Asia-Pacific
Asia Pacific is poised to grow at the highest CAGR of during the forecast period. This growth is driven by massive investments in biotechnology by the Chinese government, the expansion of CDMO services in India and South Korea, and an increasing focus on addressing the regional burden of infectious and metabolic diseases. The region is also becoming a hub for clinical trials due to its large patient populations and improving regulatory standards.
Competitive landscape
- Moderna, Inc. (U.S.)
- BioNTech SE · Germany
- Alnylam Pharmaceuticals, Inc. (U.S.)
- Ionis Pharmaceuticals, Inc. (U.S.)
- Sarepta Therapeutics, Inc. (U.S.)
- Arrowhead Pharmaceuticals, Inc. (U.S.)
- CureVac N.V. · Germany
- Translate Bio (Sanofi) · France
- Silence Therapeutics plc (U.K.)
- CRISPR Therapeutics AG · Switzerland
Frequently asked questions
The global RNA therapeutics market is expected to reach USD 40.98 billion by 2036 from an estimated USD 18.44 billion in 2026, at a CAGR of 8.3% during the forecast period 2026–2036.
Cite this report
Meticulous Research. (2026). RNA Therapeutics Market - Global Opportunity Analysis and Industry Forecast (2026-2036) (Report No. MR-1874). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/rna-therapeutics-market-6557